摘要
目的观察普拉洛芬滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液治疗过敏性结膜炎患者的效果。方法将182例过敏性结膜炎患者随机分为对照组和观察组各91例。对照组采用普拉洛芬滴眼液治疗,观察组在对照组基础上采用重组牛碱性成纤维细胞生长因子滴眼液治疗。对比两组的临床疗效、不良反应及治疗前、治疗14 d后的BUT值、 FL评分。结果观察组的总有效率为90.11%,高于对照组的67.03%(P <0.05)。治疗前,两组的BUT值、 FL评分比较无统计学差异(P>0.05);治疗后,两组的FL评分均下降,BUT值均提升,且观察组的FL评分低于对照组,BUT值高于对照组(P <0.05)。两组的不良反应发生率比较差异无统计学意义(P>0.05)。结论普拉洛芬滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液治疗过敏性结膜炎效果显著,可提高BUT值,降低FL评分,且安全可靠。
Objective To observe the effect of pranoprofen eye drops combined with recombinant bovine basic fibroblast growth factor eye drops in the treatment of patients with allergic conjunctivitis.Methods 182 patients with allergic conjunctivitis were randomly divided into two groups equally.The control group was treated with pranoprofen eye drops,and the observation group was treated with recombinant bovine basic fibroblast growth factor eye drops based on the control group.The clinical efficacy,adverse reactions,and the BUT values and FL scores before and after 14 days of treatment were compared between the two groups.Results The total effective rate of the observation group was 90.11%,higher than 67.03%of the control group(P<0.05).Before treatment,no statistical difference was found in the BUT value and FL score between the two groups(P>0.05).After treatment,the FL scores of the two groups decreased,and the BUT values increased(P<0.05);The FL score of the observation group was lower than that of the control group,and the BUT value was higher than that of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Pranoprofen eye drops combined with recombinant bovine basic fibroblast growth factor eye drops has significant effect in the treatment of allergic conjunctivitis,which can improve the BUT value,reduce the FL score,and is safe and reliable.
作者
王博
WANG Bo(Department of Ophthalmology,Nanyang Second People's Hospital,Nanyang 473000,China)
出处
《临床医学工程》
2020年第11期1469-1470,共2页
Clinical Medicine & Engineering
